Table 1:
Sample characteristics by cohort.
| Cohort | Samples (N) | Average Age (±SD) |
|
Disease Status | Proteins |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Male (%) | Cases (%) | Control (%) | Others/MCI (%) | NfL | NG | sTREM2 | VILIP-1 | SNAP-25 | |||
|
| |||||||||||
| ADNI | 689 | 73.49 (±7.56) | 57.33 | 75.33 | 21.63 | 3.05 | 152 | 55 | 684 | 58 | 57 |
| Knight ADRC | 870 | 70.88 (±8.69) | 45.98 | 20.46 | 71.95 | 7.59 | 221 | 841 | 323 | 179 | 173 |
| DIAN | 115 | 41.12 (±10.18) | 49.57 | 62.61 | 31.30 | 6.09 | NA | NA | 113 | NA | NA |
| Barcelona -1 | 92 | 70.03 (±7.51) | 57.61 | 25.00 | 1.08 | 73.91 | NA | 92 | NA | NA | NA |
Characteristics of samples with both SOMAscan and immunoassay-based protein measurements, matched based on subject ID and cerebrospinal fluid (CSF) draw date, between the platforms within each cohort. Age and disease status correspond to age and status recorded at CSF draw date. Age is reported in years (mean± SD). Cases represent sporadic AD cases for ADNI, Knight-ADRC and Barcelona 1 and autosomal dominant AD cases for DIAN. Subjects with disease status other than AD or control were grouped under “Others” category. NA values denote that no information was available for the protein within that cohort. Sample number differed between aptamers targeting the same biomarker. The highest number of samples used is reported if applicable.